Zhongnan hospital, second affiliated hospital of Wuhan University School of Medicine, wuchang, wuhan-430071, Hubei province, P.R China.

Zhongnan hospital, second affiliated hospital of Wuhan University School of Medicine, wuchang, wuhan-430071, Hubei province, P.R China.

Zhongnan hospital, second affiliated hospital of Wuhan University School of Medicine, wuchang, wuhan-430071, Hubei province, P.R China.
Hepatocellular carcinoma ,Hepatic resection ,Transcatheter arterial chemoembolization ,

Primary liver cancer (hepatocellular carcinoma) is one of the most common malignant tumor and the third most common cause of cancer related deaths. Liver transplantation, hepatic resection and ablative therapy are generally considered to be the curative treatment available for hepatocellular carcinoma (HCC). Hepatic resection is considered the gold standard for the treatment of HCC. Curative hepatic resection has shown to improve disease free survival in the last two decades. However, tumor recurrence in the remnant liver after hepatic resection of HCC is the very common and affects the long term prognosis of the patient. Preventive and aggressive management of the recurrence is important to ensure improvement in overall survival of the patients. Transcatheter arterial chemoembolization (TACE) is the most widely used procedure as an adjuvant therapy with hepatic resection for HCC. Studies have shown that hepatic resection with adjuvant TACE have shown to improve the disease free survival of the patient than resection alone.

7 , 5 , 2017